Related Experiment Videos

Tumor necrosis factor alpha decreases 1,25-dihydroxyvitamin D3 receptors in osteoblastic ROS 17/2.8 cells

N Mayur1, S Lewis, B D Catherwood

  • 1Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia.

Insights

Tumor necrosis factor alpha (TNF-alpha) reduces vitamin D receptor (VDR) number in osteoblasts, impacting bone remodeling. This suggests TNF-alpha interferes with vitamin D signaling at a post-transcriptional level.

Area of Science:

  • Molecular Endocrinology
  • Bone Biology
  • Cell Signaling

Background:

  • Bone remodeling is a dynamic process influenced by hormones and cytokines.
  • Tumor necrosis factor alpha (TNF-alpha) negatively impacts osteoblast function and promotes osteoclast activity.
  • TNF-alpha inhibits 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3)-stimulated synthesis of bone gla protein (BGP).

Purpose of the Study:

  • To investigate the hypothesis that TNF-alpha affects the number or function of the intracellular 1,25-(OH)2D3 receptor (VDR).
  • To elucidate the mechanism by which TNF-alpha influences vitamin D signaling in osteoblasts.

Main Methods:

  • Osteoblastic ROS 17/2.8 cells were cultured with or without TNF-alpha.
  • Specific binding of [3H]1,25-(OH)2D3 to VDR in cytosol extracts was measured.
  • VDR mRNA levels were analyzed using Northern blot.

Main Results:

  • TNF-alpha treatment significantly decreased specific [3H]1,25-(OH)2D3 binding by 70% within 25 hours.
  • Scatchard analysis indicated TNF-alpha reduced the number of VDR binding sites without altering VDR affinity.
  • VDR mRNA levels remained unchanged, suggesting TNF-alpha acts post-transcriptionally.

Conclusions:

  • TNF-alpha exerts an inhibitory effect on VDR number in osteoblastic cells.
  • This reduction in VDR occurs at a level distal to VDR mRNA synthesis.
  • The findings reveal a novel mechanism for TNF-alpha's interference with vitamin D action in bone cells.

Related Concept Videos